

11-14-00

A

Express Mail Label No. EL566557328US

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
RDID0006USTotal Pages in this Submission
63

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for invention entitled:

SYSTEM FOR THE EXTRAPOLATION OF GLUCOSE CONCENTRATION

and invented by:

Brit KALATZ and Udo HOSS

If a CONTINUATION APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Which is a:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: _____

Enclosed are:

Application Elements

1. ☐ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 24 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☐ Cross References to Related Applications (if applicable)
 - c. ☐ Statement Regarding Federally-sponsored Research/Development (if applicable)
 - d. ☐ Reference to Microfiche Appendix (if applicable)
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☒ Brief Description of the Drawings (if drawings filed)
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

11/13/00

JC903 U.S. PTO

JC903 U.S. PTO
09/711855

11/13/00

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
RDID0006US

Total Pages in this Submission
63

Application Elements (Continued)

3. ☒ Drawing(s) (when necessary as prescribed by 35 USC 113)
- a. ☒ Formal Number of Sheets 4
- b. ☐ Informal Number of Sheets _____
4. ☒ Oath or Declaration
- a. ☐ Newly executed (original or copy) ☒ Unexecuted
- b. ☐ Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
- d. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference (usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Computer Program in Microfiche (Appendix)
7. ☐ Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
- a. ☐ Paper Copy
- b. ☐ Computer Readable Copy (identical to computer copy)
- c. ☐ Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. ☐ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(B) Statement (when there is an assignee)
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
12. ☒ Preliminary Amendment (to follow)
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
- ☐ First Class ☒ Express Mail (Specify Label No.): EL566557328US

UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
RDID0006US

Total Pages in this Submission
63

Accompanying Application Parts (Continued)

15. ☒ Certified Copy of Priority Document(s) (if foreign priority is claimed)
16. ☒ Additional Enclosures (please identify below):

General Appointment of Representative for U.S. Patent and Trademark Office Matters (1pp).

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims		- 20 =	0	x \$18.00	\$0.00
Indep. Claims		- 3 =	0	x \$78.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$0.00
OTHER FEE (specify purpose)					\$0.00
TOTAL FILING FEE					\$0.00

- ☐ A check in the amount of _____ to cover the filing fee is enclosed.
- ☐ The Commissioner is hereby authorized to charge and credit Deposit Account No. _____ as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____ as filing fee.
- ☐ Credit any overpayment.
- ☐ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).


Signature

Richard T. Knauer, Reg. No. 35,575
Roche Diagnostics Corporation
9115 Hague Road, Bldg. D
P.O. Box 50457
Indianapolis, IN 46250-0457
Telephone No.: (317) 521-7464
Facsimile No.: (317) 521-2883

Dated: November 13, 2000

cc:

System for the Extrapolation of Glucose Concentration

This invention provides a system for the extrapolation of an actual glucose concentration in order to determine future glucose concentrations. Another configuration of the system uses extrapolated glucose concentrations to determine the proper dose of insulin to administer to a patient.

Diabetes mellitus is a group of chronic metabolic disorders characterized by raised blood glucose levels and impaired carbohydrate, fat, and protein metabolism. The insulin deficiency responsible for this disorder results from a defect in insulin secretion or the effect of insulin on the organism. Absolute insulin deficiency—which occurs in type I diabetes—is usually caused by an auto-immunological destruction of insulin-producing beta cells in the pancreas. These patients must rely on exogenous sources of insulin. Individuals with type II diabetes are resistant to insulin and suffer from impaired insulin secretion. Both of these disorders can occur to varying degrees. The exact causes of this disease are not known. Treatment of relative insulin deficiency ranges from dietary modifications and oral anti-diabetics to exogenous insulin administration.

Patients who suffer from Diabetes mellitus over the long term and, therefore, have chronic hyperglycemia, develop organ damage, impairment, and even failure. The eyes, kidneys, nerves, blood vessels, and the heart are affected in particular. Prevention of these late complications is the main goal of diabetes therapy. In the most commonly used therapy today, patients are administered slow-acting insulin that covers the basal insulin demand. They are also administered a bolus of normal insulin or a fast-acting insulin to offset the carbohydrates consumed during a meal.

This invention concerns the extrapolation of measured glucose concentrations to determine future concentrations in order to provide the patient with the basis for determining proper insulin dosage, or to properly control an insulin infusion pump.

A biostator is known in the prior art that is used to perform glucose measurements in venous blood and administer computer-controlled intravenous insulin and glucose infusions based on these measurements. A serious disadvantage of the biostator, however, is that intravenous infusions must be carried out to achieve proper regulation, and these infusions basically must be performed under stationary conditions. The patient cannot perform the infusion himself due to the high risk of infection.

The goal of development work, therefore, must be to maintain patients within a normal range of glucose concentration by means of subcutaneous insulin infusions that can be carried out by the patient himself or by means of implanted pumps. Due to the delayed effect of subcutaneously administered insulin, however, is it much more difficult to find a control procedure with which the goal can be achieved. U.S. patent 5,822,715 describes a diabetes management system with which an insulin dose to be injected by the patient is determined based on measured blood glucose values and previously administered insulin doses. To calculate the insulin dose to be administered, a future blood glucose value is calculated for this patient, and its deviation from a target blood glucose value is determined. This procedure only takes into consideration the administered insulin doses and their effectiveness profile, however. Other influences on blood glucose concentration are not explicitly taken into consideration. Our studies show that consideration of administered insulin quantities alone is not sufficient to keep glucose concentration within a normal range. It was found in particular that cases of strong hyperglycemia occur in regulating procedures based solely on this technique.

The object of the present invention was to propose a system for the reliable extrapolation of a glucose concentration and the determination of insulin doses to be administered subcutaneously. It was found with the invention that it is particularly important to take consumed carbohydrates into account when developing a regulating system that achieves the goal of subcutaneous insulin infusion. Accordingly, this invention provides a system for the extrapolation of glucose concentrations, comprising

- a data input device (EI) for entering the insulin doses (I_i) administered to the patient and their times of administration (t_i),
- data input device (EK) for entering the carbohydrates (KH_j) consumed or to be consumed by the patient, and the time they are consumed (t_j),
- a unit (GM) for determining the actual glucose concentration (G_a) in a patient's bodily fluid at a specific point in time (t_a),
- a memory unit (M) for storing the insulin doses administered and their times of administration, and the carbohydrates consumed and the times they were consumed,
- an evaluation device for evaluating the data stored in the memory unit and for extrapolating a glucose concentration at a point in time (t_p) that is later than the time of measurement (t_a), and whereby the extrapolation comprises the following steps:
 - determination of the portion (I_{wirk}) of insulin doses that take effect within the interval between measurement and the projected moment,
 - determination of the portion (KH_{wirk}) of carbohydrates consumed that take effect within the interval between measurement and the projected moment,
 - determination of an extrapolated glucose concentration (G_p) with consideration for the effective insulin doses (I_{wirk}) and the effective carbohydrate intake (KH_{wirk}).

A system according to the invention comprises a data input device (EI) for entering administered insulin doses and their times of administration. This data input device can be a keyboard, for instance, by means of which the patient himself enters the insulin dose that he administered or had administered. The time of administration can be entered manually as well. The data input device could also be combined with a clock so the patient has the option of selecting time of input as the time of administration. It is also possible to combine a device that performs the administration, e.g., an automatic insulin pump, with a transmission device that transmits the administered insulin dose and its time of administration to the data input device. This transmission can take place over a fixed wire or via telemetric connection. It is also possible that the patient operates an infusion

device himself, such as an insulin pump outfitted with a transmission unit that transmits the administered insulin dose along with the time of administration to the data input device.

The system also comprises a unit (GM) that determines a glucose concentration at a specific point in time. Blood glucose meters are known in the prior art with which glucose concentration can be measured in a capillary blood sample collected by the patient from the fingertip and then applied to a test element, for instance. These devices will not be described in further detail because they have been known for some time. To determine blood glucose values, it is also possible to implant measurement sensors in the body (e.g., intravascular, interstitial). This technology has not become popular because the sensors tend to drift. Another possibility for the determination of glucose values is based on measurements in interstitial fluid. Devices are known, for instance, with which small quantities of interstitial fluid can be collected through thin cannula and then analyzed. To perform subcutaneous measurements it is also possible to implant miniaturized catheters with which microdialysis or ultrafiltration can be performed, so that measured results can be provided at close intervals. A device based on microdialysis is described in U.S. patent 5,174,291, for instance. A device based on the principle of ultrafiltration is described in U.S. patent 4,777,953. These devices will not be discussed in further detail here.

The carbohydrates consumed by the patient and their time of consumption are recorded by a second data input device (EK). However, data input devices for insulin doses and carbohydrates can be provided by the same physical device, e.g. a keyboard, for entering both, administered insulin doses as well as consumed carbohydrates. Currently, diabetics typically estimate their insulin demand themselves based on the quantity of carbohydrates they consumed or are planning to consume, and then inject themselves with the calculated insulin dose before or directly after eating. The diabetic determines carbohydrate units by calculating the number of bread exchanges using tables for different types of food. According to the invention, the diabetic, nurse, or another caregiver enters the number of carbohydrate units or bread exchanges determined in the second data input device. This can be accomplished using a keyboard that is part of the

system, for instance. Since the determination of carbohydrates consumed or to be consumed is relatively inaccurate by nature, one can use preprogrammed keys to enter a small, normal, or heavy meal, instead of a numerical entry. The system assigns 2, 4, or 6 carbohydrate units to these keys, for instance, which are used in the formula described below. It is also possible to provide selection keys or a selection field with which values in bread exchange increments of 0.5 can be entered. It is important that the times of carbohydrate consumption also be entered as accurately as possible. To ensure this, a clock can be provided in the data input device or the system that selects the time of input as the time of carbohydrate consumption and pairs it with the value of carbohydrate units consumed. The system should also provide an option for the user to change this time or to enter it himself directly if necessary.

The system also comprises a memory unit (M) for storage of administered insulin doses and their times of administration, as well as carbohydrate units consumed and their times of consumption, so they can be used as the basis for a subsequent evaluation. Such memory components—known as RAM—have been known for some time in the prior art.

An important component of the present system is an evaluation unit for the evaluation of data stored in the memory unit according to a predetermined evaluation procedure. As mentioned previously, the evaluation unit performs an extrapolation, by means of which a future glucose concentration (G_p) is determined. It was found that such an extrapolated glucose concentration is a suitable control variable for the determination of required insulin or glucose doses, and for the early detection of hypoglycemia or hyperglycemia. The extrapolation includes the determination of the portion of insulin dose that will become effective in the interval between measurement and the extrapolated point in time, and the determination of the portion of the carbohydrates consumed that takes effect in this time interval. In accordance with the invention it was found that these two parameters are the most important, and that taking them into account leads to an extrapolated glucose concentration that allows for a sufficiently exact determination of future glucose concentrations and required insulin doses. The effectiveness of the

determination procedure based on this method will be demonstrated later using experimental data.

The portion (I_{wirk}) of insulin doses that become effective in the interval between the actual measurement (t_a) and the extrapolated point in time (t_p) can be determined by taking into account the kinetics of effectiveness of the insulin used.

Figure 1 shows effectiveness profiles of human insulin and Lispro after subcutaneous injection. Systems based on the present invention are especially well-suited for use with fast-acting insulins such as Lispro and Aspart.

The portion of insulin that takes effect in the period between measurement and the projected point in time can be calculated by first determining how much time has passed since administration of the insulin and the current point in time. In Figure 1, for instance, the measurement (t_a) occurred 1.5 hours after insulin infusion. Three hours was selected as the projection period, so t_p can be found at 4.5 hours on the time axis shown. The portion of the insulin that is effective in the projection period can be determined by integrating the curve between t_a and t_p and multiplying this value by the number of insulin units administered. This method of calculation is based on the fact that the insulin effectiveness curve is scaled in such a way that the area under the complete curve is 1 (one), so that the integral between two points in time provides the portion directly that takes effect in the period involved. If numerous insulin doses make a contribution within the projection period, this is taken into account by adding up the individual contributions by using the calculation procedure described for each insulin dose individually. It is also possible to take contributions from different types of insulin into account by basing the calculation on the effectiveness profile of each type. A calculation formula that takes into account numerous insulin doses—of the same type of insulin, however—is as follows:

$$I_{\text{wirk}} = \sum_{i=1}^n \int_{t_a}^{t_p} C_i(t) dt * I_i \quad (1)$$

In the formula above, C stands for the portion of insulin that is bioavailable at the time t , which corresponds to the value of the ordinate in Figure 1. The factor I_i indicates the dose administered via injection i . The zero point in time for each addend is the time of administration of the respective insulin dose. n indicates the number of insulin doses taken into account in the calculation. Which insulin doses are taken into account depends on the effectiveness profile of the insulin used and the time interval between administration and the actual point in time t_a . Figure 1 indicates that the effect of Lispro has worn off 6 hours after administration. This means that doses of Lispro that are administered more than 6 hours before the current point in time do not need to be taken into account.

In practice, the integration indicated in formula (1) can be greatly simplified if the insulin effectiveness profile is approximated by a linear increase and a linear decrease. The experimental results shown below are based on such an approximation and show that this is a feasible method for practical use. For purposes of the present invention, the integral representation used in formula (1) stands for all types of determination that—either directly or indirectly—determine a portion of the insulin that will become effective in the projection period by integrating an effectiveness profile. As an example, it is also possible to use a function (transformation) $F_I(t)$ for this purpose:

$$F_I(T) = \int_0^T C_I(t) dt \quad (2)$$

$F_I(T)$ indicates the portion of insulin that takes effect from the moment of injection until the point in time T . The portion of insulin that takes effect in the projection period is determined with the transformation as follows:

$$I_{\text{wirk}} = F_I(t_p) - F_I(t_a) \quad (3)$$

By storing the integral function F_I (e.g., in a table), the subsequent calculation of I_{wirk} can be traced back to a simple subtraction.

Figure 2 shows an approximation of the effectiveness profile using a triangulation function. Insulin was administered at the point in time t_b , and the glucose concentration was measured at the point in time t_a . A projection period of 2 hours was selected. The shaded triangular area therefore corresponds to the portion of insulin that is effective in the projection period.

As described earlier, the system was improved considerably by taking into account the quantity of carbohydrates that is effective in the projection period. If a carbohydrate effectiveness profile ($C_{KH}(t)$) that is known or assumed to be valid is used as the basis, the effective portion of carbohydrates is determined as follows:

$$KH_{\text{wirk}} = \sum_{j=1}^m \int_{t_a}^{t_p} C_{KH}(t) dt * KH_j \quad (4)$$

This formula uses the factor KH_j to take into account the consumption of carbohydrates at numerous points in time, as well as the quantity of carbohydrate units consumed each time. The zero point in time is represented in this case by the time of carbohydrate consumption. The integration indicated in formula (4) stands for all types of determination that—either directly or indirectly—determine a portion of the carbohydrates that will become effective in the projection period by integrating a carbohydrate effectiveness profile, as in formula (1). Due to the commonly used scaling,

$$\int_0^{\infty} C_{KH}(t) dt = 1$$

this also includes methods in which integration of the curve outside the projection period and subtraction of this integral is used to determine the effective portion of insulin in the projection period. The complex integration can be eliminated when calculating the

carbohydrates that are effective within the projection period if an idealized carbohydrate effectiveness profile is used as the basis, or if the same approach is used to determine the effective portion of insulin using a transformation $F_{KH}(T)$:

$$F_{KH}(T) = \int_0^T C_{KH}(t) dt \quad (5)$$

KH_{wirk} is calculated as follows:

$$KH_{wirk} = F_{KH}(t_p) - F_{KH}(t_a), \quad (6)$$

whereby t_p and t_a are determined based on carbohydrate consumption. The effectiveness of the carbohydrates in the organism is given by the glucose “flooding”. Glucose “flooding” describes the appearance of glucose in the organism that can be measured, e.g., in blood, after food intake or as a result of hepatic glucose production. Glucose flooding itself depends on various factors. It is known to be affected by the stomach emptying rate, the glucose absorption rate from the duodenum, and the degree of hepatic glucose consumption. It was found, however, that the stomach emptying rate is the step that controls the speed of glucose “flooding”. It was also found in carbohydrate absorption studies that glucose flooding increases quickly at first, plateaus briefly (10), then drops slowly (12). A time of between 10 and 25 minutes and, most preferably, about 15 minutes, is selected as the delay between carbohydrate consumption and the onset of glucose flooding. The plateau (10) of glucose flooding is preferably selected as 15 to 25% of the total period of glucose flooding (t_{KH}), which is indicated as follows:

$$t_{KH} = Q * KH_j \quad (7)$$

whereby Q is a factor in the range of 2 to 10 min/g and preferably 5 min/g, and KH_j is the quantity of carbohydrates consumed in grams.

Figure 3 shows a model that was used as a basis in subsequent experiments. In Figure 3, the moment of carbohydrate consumption is indicated as t_e , and the time of measurement is indicated as t_a . The time to which the glucose concentration should be projected is indicated as t_p . The portion of effective carbohydrates is therefore shown as the area described as $A_2 - A_1$.

The present invention can be used with different models of the glucose flooding rate. Based on the experiments conducted, however, it was found that the course of glucose flooding shown in Figure 3 forms a good basis for the extrapolation of glucose concentration. The shape of the curve shown in Figure 3 is determined by the following parameters:

Time interval (t_z) between carbohydrate consumption and the onset of glucose flooding, the duration of the plateau (t_{PLATEAU}), and the duration (t_{DROP}) of the drop in glucose flooding. The following parameters empirically were found to be especially favorable:

$$t_z = 15 \text{ min}$$

$$t_{\text{PLATEAU}} = 0.2 * t_{\text{KH}}$$

$$t_{\text{DROP}} = 0.8 * t_{\text{KH}}$$

The entire area below the glucose flooding curve was scaled as 1. The slope of the drop is therefore determined by the height of the plateau and the duration of the drop. The effective carbohydrates (KH_{wirk}) can therefore be determined based on an entire area of 1.

The extrapolated glucose concentration can be calculated as follows based on the insulin doses that are effective in the projection period (I_{wirk}) and the carbohydrate units (KH_{wirk}) that are effective in the projection period:

$$G_p = G_a - I_{\text{wirk}} * D * SE + \text{KH}_{\text{wirk}} * E + X \quad (8)$$

As a prerequisite for this formula it is assumed that the actual glucose concentration (G_a) at the time of measurement is decreased proportionally to the patient's insulin sensitivity by the effective insulin units in the projection period. This proportionality is taken into account by the empirical weighting factor D which, according to experiments, is between 0.05 and 0.5 mmol/l/g. Insulin sensitivity means simply the quantity of carbohydrate units that can be compensated by one unit of insulin. Insulin sensitivity fluctuates depending on the time of day, and is dependent on other physiological factors as well. In practice, however, simply estimating a patient's insulin sensitivity has become very significant, because the patient can use it to calculate the approximate quantity of insulin that he must inject to offset the glucose flooding expected after an upcoming meal. To do this, the patient uses tables to determine the number of bread exchanges (equivalent to carbohydrate units) that he will consume at the meal and multiplies this value by his estimated insulin sensitivity in order to calculate his insulin dose.

Formula 8 is also based on the fact that the actual glucose value (G_a) in the projection period is increased proportionally to the carbohydrate units that are effective in this period. This proportionality is taken into account with the factor E . It was found that it is favorable to use $R_{KH} * F$ as E , whereby F is a factor close to 0.25 mmol/l/g, and R_{KH} is the carbohydrate reduction factor. The carbohydrate reduction factor is used to reduce the effect of carbohydrates on blood glucose concentration in the calculation.

The additive variable X in formula 8 can be determined based on empirical studies. However, $G_{\text{basal}} = I_{\text{basal}} * SE * C$ is preferably used as X . In this case, X takes into account the fact that blood glucose is also increased by basal insulin demand (I_{basal}) during the projection period. This increase in glucose concentration is considered to be proportional to insulin sensitivity, whereby the empirical weighting factor C takes this proportionality into account. C is preferably between 0.05 to 0.5 mmol/l/g.

In addition or as an alternative, the variable X can contain the variable $SG * A$ as the addend. SG (unit: mmol/l/g) corresponds to the increase in glucose concentration at the

time of measurement (t_a), and A is an empirical weighting factor that is preferably between 0 and 100 min.

As described earlier, a main goal of this invention is to keep a patient's glucose concentration within a normal range. Although most experts consider the normal range to be a glucose concentration of between 3.5 and 10 mmol/l, others disagree. These values should therefore be considered to be guide values. A system based on the present invention can contain a warning unit that compares the extrapolated glucose concentration (G_p) with a programmed normal range and sounds a warning signal when the extrapolated glucose concentration lies outside this range.

A system based on this invention can also include a control unit that controls an insulin infusion device such as an insulin pump. The system can also have a display or another type of output device that is used to suggest an insulin dose to the patient which he then administers himself or has administered. It is especially favorable if the insulin is infused automatically by the device but the patient can control it if necessary. This can be achieved by including a release unit in the system that the patient can use to intentionally release an insulin dose suggested by the system. For instance, the system can display a calculated insulin dose and wait for a key to be pressed before it administers the insulin (e.g., using an insulin pump).

The insulin dose (ID) can be calculated based on the following formula:

$$ID = ((G_p - G_R) / SE * E) + Y \quad (9)$$

In formula 9, G_p stands for the extrapolated glucose concentration, and G_R represents a target glucose concentration within the normal range or a maximum acceptable glucose concentration. The formula also contains the patient's insulin sensitivity (SE), the empirical factor E, and an additive variable Y. Experiments have shown that $K_R * KH_{Rest} / SE * F$ is a favorable choice for Y. In this formula, R_{KH} represents the carbohydrate reduction factor. KH_{Rest} is the quantity of carbohydrates resorbed between the actual time

(t_a) and the end of effectiveness of the insulin dose that was administered. The effective period (T_I) for Lispro is about 4 hours, and about 6 hours for human insulin from the time of administration. In terms of the present invention, values are included for the effective period (T_I) of insulin for which the integral

$$\int_0^{T_I} C_I(t) dt \text{ is between } 0.8 \text{ and } 1.$$

This approach also takes into account carbohydrate effects that take place after the projection period.

It has proven to be advantageous to design a system based on the present invention with an automatic measuring device for determining glucose concentration with which measurements can be performed at regular intervals without user intervention. The current glucose concentration and insulin dose to administer are preferably determined at intervals of between 1 and 30 minutes. As mentioned earlier, this type of quasi continual monitoring of glucose concentration can be performed especially well with a microdialysis system. An insulin infusion device can be integrated in such a system or in other sensors. The advantage of this design is that just one unit need be implanted in the patient's body.

The design and function of a system based on the invention for extrapolation of a glucose concentration or for determination of an insulin dose to be administered is described in greater detail using the following figures:

Figure 1: Effectiveness profile of human insulin and Lispro

Figure 2: Approximation of the effectiveness profile of a fast-acting insulin using a triangulation function

Figure 3: Model of glucose flooding rate after a meal

Figure 4: Schematic representation of the system units

Figure 5: Glucose / time profile and administered insulin doses, and quantities of carbohydrates consumed

Figures 1 through 3 were described in the text above.

Figure 4 shows the schematic representation of a system based on the present invention. A first data input device (EI) communicates the insulin doses, types, and times of administration to the evaluation unit (CPU). As described above, the data input device can be a keyboard or another type of device for manual data input. It can also be a data input device that receives signals from another device such as an insulin pump. The evaluation unit also receives data on the carbohydrates consumed and their times of consumption from a second data input device (EK). The second data input device can also be a keyboard (e.g. the same as for the first data input device) or another type of device for manual input of data. An option can also be included for specifying the type of food consumed in such a way that describes how its carbohydrate reduction factor or its resorption by the organism takes place over time. It was found, for instance, that dextrose is resorbed and initiates glucose flooding much more quickly than highly fatty meals, for instance.

Figure 4 also shows that the evaluation unit receives data from the unit (GM) to determine an actual glucose concentration. These data do not necessarily have to be individual glucose concentrations. It can also be designed to transmit all the values measured at different intervals over a specified period of time collectively. The transmitted glucose concentration values can be calculated in the evaluation unit in order to determine the slope of the glucose concentration. This calculation can also be carried out in the GM unit, however, and these data can be transferred to the evaluation unit.

As illustrated in the previous description, the evaluation unit (CPU) uses the information received to determine a future glucose concentration and/or an insulin dose to be administered. The units shown below the dotted line in Figure 4 constitute a system according to the invention. The output unit (AE) shown above the dotted line is optional, however. The output unit can be a display, for instance, that displays the extrapolated glucose concentration or an insulin dose to be administered. As an alternative, future glucose concentrations can also be determined for a number of different points in time, and the resulting curve can be displayed. An output unit can also be a warning unit that warns the patient about an impending hypoglycemic or hyperglycemic condition if the extrapolated glucose value is outside the prescribed normal range. An insulin infusion device such as an insulin pump can also be used as the output unit, so that the evaluation unit initiates the administration of insulin either directly or by means of a control unit with the administration device. As described above, the system can also be designed so that the user or caregiver has the option of approving administration of the insulin dose.

Figure 5 shows a 24-hour study in which blood samples were drawn from a patient at 12 and 36-minute intervals. The glucose concentration of these samples was then tested on a Glucotrend from Roche Diagnostics GmbH and an Hitachi 911 automated analyzer. The black squares in Figure 5 represent the blood glucose concentrations measured with the Glucotrend (shown on the left ordinate), and open circles represent the concentrations measured on the Hitachi analyzer. Figure 5 also shows 3 meals consisting of 50, 60, and 60 [sic] grams of carbohydrates at the times indicated by the arrows. Insulin doses were calculated and administered based on calculations using formula 9 while taking into account an insulin effectiveness kinetic according to Figure 2 and a glucose flooding rate according to Figure 3. These insulin doses and administrations are represented by empty bars in Figure 5. The insulin dose administered in each case is indicated by the height of the bars on the right ordinates. Figure 5 shows that blood glucose concentration increases significantly after meals and cannot be completely compensated by previous insulin doses. It also shows that the insulin doses helped to limit the increase in blood glucose concentration to values below 225 mg/dl. After the third meal, the insulin doses helped achieve a stable blood glucose concentration of about 150 mg/dl. Figure 5 also indicates

Claims

1. System for the extrapolation of a glucose concentration, comprising
 - a data input device (EI) for entering insulin doses administered (I_i) and their times of administration (t_i),
 - the same or a second data input device (EK) for entering carbohydrates (KH_j) consumed or to be consumed, and their times of consumption (t_j),
 - a unit (GM) for determining the actual glucose concentration (G_a) in a patient's bodily fluid at a specific point in time (t_a),
 - a memory unit (M) for storing administered insulin doses and their times of administration, and carbohydrates consumed and their times of consumption,
 - an evaluation device (CPU) for evaluating the data stored in the memory unit and extrapolating a glucose concentration at a point in time (t_p), whereby t_p is after t_a , and the extrapolation comprises the following steps:
 - determination of the portion (I_{wirk}) of insulin doses that take effect within the interval between t_a and t_p ,
 - determination of the portion KH_{wirk} of carbohydrates consumed that take effect in the interval between t_a and t_p ,
 - determination of an extrapolated glucose concentration G_p at the point in time t_p with consideration for I_{wirk} and KH_{wirk} .
2. System according to Claim 1, in which the glucose concentration G_p is determined at the point in time t_p using the following formula:

$$G_p = G_a - I_{\text{wirk}} * D * SE + KH_{\text{wirk}} * E + X,$$

whereby D is an empirical weighting factor, SE is the patient's insulin sensitivity, E is a factor, and $X = 0$ or is unequal to zero.

3. System according to Claim 2, in which $E = R_{KH} * F$, whereby R_{KH} is the carbohydrate reduction factor and F is an empirical factor.

4. System according to Claim 2, in which X, as the addend, contains the quantity G_B
 $= I_{\text{basal}} * SE * C$ or is equal to G_B , whereby I_{basal} is the patient's basal insulin
demand over 24 hours, SE is the patient's insulin sensitivity, and C is an empirical
weighting factor.
5. System according to Claim 2 or 4, in which X, as the addend, contains the
quantity $SG * A$, whereby SG is the slope of the glucose concentration at the
point in time t_a , and A is an empirical weighting factor.
6. System according to Claim 1, in which the unit used to determine the actual
glucose concentration G_a is a microdialysis device.
7. System according to Claim 1 that also includes a display unit for displaying the
extrapolated glucose concentration G_p .
8. System according to Claim 1 that also includes a warning unit that emits a
warning signal when the extrapolated glucose concentration G_p is outside a
selected normal range.
9. System according to Claim 1 in which the user enters the carbohydrate units
consumed (KH_j).
10. System according to Claim 1 in which the system contains a control unit for an
insulin infusion device or is connected to such a device, and in which the insulin
doses administered (I_i) and their times of administration (t_i) are transmitted from
the control unit to the data input device for entering insulin doses.

11. System according to Claim 1 or 2 in which the portion of insulin doses (I_{wirk}) that take effect in the period between t_a and t_p is calculated using the following formula

$$I_{\text{WIRK}} = \sum_{i=1}^n \int_{t_a}^{t_p} C_i(t) dt * I_i; \text{ n = number of insulin doses to be considered}$$

whereby C_I represents the quantity of insulin that is bioavailable at the point in time t and therefore represents the insulin effectiveness profile; with

$$\int_0^{\infty} C_I(t) dt = 1.$$

12. System according to Claim 1 or 2 in which the quantity of carbohydrates consumed (KH_{wirk}) that takes effect in the period between t_a and t_p is calculated using the following formula

$$KH_{\text{WIRK}} = \sum_{j=1}^m \int_{t_a}^{t_p} C_{KH}(t) dt * KH_j$$

whereby C_{KH} represents the quantity of carbohydrates that are bioavailable at the point in time t and therefore represents the carbohydrate flooding profile, with

$$\int_0^{\infty} C_{KH}(t) dt = 1.$$

13. System for determination of insulin doses to be administered comprising
- a data input device (EI) for entering the insulin doses administered to the patient (I_i) and their times of administration (t_i),

- a device (GM) for determining the actual glucose concentration G_a in a patient's bodily fluid at a specific point in time (t_a),
 - a memory unit (M) for storing the doses of insulin administered and their times of administration,
 - an evaluation device (CPU) for evaluating the data stored in the memory unit, and determination of an insulin dose to be administered subcutaneously, or a carbohydrate intake whereby the evaluation comprises the following steps:
 - determination of the portion (I_{wirk}) of insulin doses that are consumed within the period between t_a and t_p ,
 - determination of the insulin doses to be administered, with consideration for I_{wirk} .
14. System according to Claim 1 or 13, in which the point in time t_p is from 0.5 to 5 hours after t_a .
15. System according to Claim 1 or 13, in which the point in time t_p is at least 2 hours after t_a and up to 4 hours after t_a .
16. System according to Claim 13, in which a glucose concentration G_p is measured at point in time t_p and this glucose concentration is used to calculate the insulin dose to be administered.
17. System according to Claim 16, in which the glucose concentration G_p at the point in time t_p is calculated using the following formula:

$$G_p = G_a - I_{\text{wirk}} * D * SE + X,$$

whereby D is an empirical weighting factor, SE is the patient's insulin sensitivity, and $X = 0$ or is unequal to zero.

18. System according to one of Claims 13 – 17 that includes a data input device (EK) for entering carbohydrate units consumed by a patient and their times of consumption, and then determines the portion (KH_{wirk}) of carbohydrate units consumed that take effect in the interval between t_a and t_p and takes KH_{wirk} into account in the determination of the insulin dose to be administered.

19. System according to Claim 18, in which the glucose concentration G_p is calculated at the point in time t_p using the following formula:

$$G_p = G_a + KH_{\text{wirk}} * E - I_{\text{wirk}} * SE * D + X,$$

whereby E and D are empirical weighting factors, SE is the patient's insulin sensitivity, and $X = 0$ or is unequal to zero.

20. System according to Claim 17 or 19, in which X, as the addend, contains the quantity $G_{\text{basal}} = I_{\text{basal}} * SE * C$, whereby I_{basal} is the patient's basal insulin demand over a 24-hour period, SE is the patient's insulin sensitivity, and C is an empirical weighting factor.

21. System according to Claim 17 or 20 in which X, as the addend, contains the quantity $SG * A$, whereby SG is the slope of glucose concentration at the point in time t_a , and A is an empirical weighting factor.

22. System according to Claim 16 or 17, in which the insulin dosage ID to be administered subcutaneously is calculated using the following formula:

$$ID = ((G_p - G_R) / SE * E) + Y, \text{ whereby}$$

G_R is a target glucose concentration or a maximum acceptable glucose concentration, E is an empirical weighting factor, and $Y = 0$ or is unequal to zero.

23. System according to Claim 22, whereby $Y = R_{KH} * KH_{REST} / SE * F$ is or contains this value as the addend, whereby R_{KH} is the patient's carbohydrate reduction factor, KH_{REST} is the quantity of carbohydrates resorbed between the actual point in time (t_a) and the end of the period in which the insulin is effective, and F is an empirical weighting factor.
24. System according to Claim 13, in which the quantity of insulin to be administered is calculated in intervals of from 1 to 30 minutes.
25. System according to Claim 13 that contains a display unit for displaying the insulin dose to be administered.
26. System according to Claim 13 that also contains a microdialysis device with a microdialysis catheter.
27. System according to Claim 13 that has an administration unit for administering a calculated insulin dose.
28. System according to Claim 27, in which the administration unit is integrated in the microdialysis catheter.
29. System according to Claim 13 that contains a query unit that performs a query to determine if a certain insulin dose should be administered and with which the user releases the administration of insulin.
30. System according to Claim 13 that contains a warning unit that emits a warning signal when an extrapolated glucose concentration G_p leaves a normal range or when an insulin dose to be administered exceeds a predefined quantity.

31. System according to Claim 13 or 27 that contains a display unit for displaying an insulin dose to be administered, as well as an editing unit which the patient can use to change the insulin dose to be administered before it is administered.

Abstract

System for the extrapolation of a glucose concentration comprising a data input device (EI) for entering administered insulin doses (I_i) and their times of administration (t_i), a data input device (EK) for entering the carbohydrates (KH_j) consumed or to be consumed, a unit (GM) for determining an actual glucose concentration (G_a) at a point in time (t_a) in a patient's bodily fluid, a memory unit (M) for storing the insulin doses that have been administered, their times of administration, carbohydrate units consumed and their times of consumption, an evaluation unit (CPU) for evaluation of the data stored in the memory unit, and for the extrapolation of a glucose concentration at a point in time t_p , whereby t_p is after t_a , and in which the extrapolation comprises the following steps:

Determination of the portion (I_{wirk}) of insulin doses that become effective between t_a and t_p ;

Determination of the portion of consumed carbohydrate units KH_{wirk} , that become effective between t_a and t_p ;

Determination of an extrapolated glucose concentration G_p at the point in time t_p with consideration for I_{wirk} and KH_{wirk} .

The invention also provides a method for the extrapolation a glucose concentration and a system for the determination of insulin doses to be administered.




Fig. 2




Fig. 3




Fig. 4




Fig. 4




Fig. 5

Docket No.
RDID0006US

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

SYSTEM FOR THE EXTRAPOLATION OF GLUCOSE CONCENTRATION

the specification of which

(check one)

☒ is attached hereto.

☐ was filed on _____ as United States Application No. or PCT International Application Number _____ and was amended on _____ (if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Not Claimed

199 55 734.9

Germany

18 November 1999

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

☐

(Number)

(Country)

(Day/Month/Year Filed)

I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

(Application Serial No.)

(Filing Date)

I hereby claim the benefit under 35 U. S. C. Section 120 of any United States application(s), or Section 365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. Section 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, C. F. R., Section 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. *(list name and registration number)*

Richard T. Knauer, Reg. No. 35,575

D. Michael Young, Reg. No. 33,819

Brent A. Harris, Reg. No. 39,215

Kenneth J. Waite, Reg. No. 45,189

Marilyn L. Amick, Reg. No. 30,444

Jill Lynn Woodburn, Reg. No. 39,874

Send Correspondence to: **Richard T. Knauer**
Roche Diagnostics Corporation
9115 Hague Road, Bldg. D, P.O. Box 50457
Indianapolis, IN 46250-0457

Direct Telephone Calls to: *(name and telephone number)*
Richard T. Knauer, Telephone No. (317) 521-7464

Full name of sole or first inventor KALATZ, Brit	
Sole or first inventor's signature	Date
Residence Johannes-Mynsinger Weg 12, D-89075 Ulm, Germany	
Citizenship German	
Post Office Address (same as residence)	

Full name of second inventor, if any HOSS, Udo	
Second inventor's signature	Date
Residence 24442 Valencia Blvd. #2102, Valencia, California 91355, United States of America	
Citizenship German	
Post Office Address (same as residence)	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents
Washington, DC 20231

**GENERAL APPOINTMENT OF REPRESENTATIVE FOR
U.S. PATENT AND TRADEMARK OFFICE MATTERS**

The undersigned applicant or assignee hereby appoints D. Michael Young, Reg. No. 33,819, Richard T. Knauer, Reg. No. 35,575, Brent A. Harris, Reg. No. 39,215, Kenneth J. Waite, Reg. No. 45,189, and Marilyn L. Amick, Reg. No. 30,444 all of Roche Diagnostics Corporation, 9115 Hague Road, P.O. Box 50457, Indianapolis, Indiana 46250, Telephone No. (317) 845-2000, and Jill Lynn Woodburn, Reg. No. 39,874 of The Law Office of Jill L. Woodburn, L.L.C., 6633 Old Stonehouse Drive, Newburgh, Indiana 47630-1785, Telephone No. (812) 842-2660:

to prosecute and transact all business on its behalf before the United States Patent and Trademark Office in connection with any U.S. patent assigned to it and any U.S. patent application filed by it or on its behalf and to receive payments on its behalf.

Signed this 18th day of September, 2000 at Mannheim, Germany.

Roche Diagnostics GmbH


Signature


Dr. Michael Jung

Print Name

Director

Position or Title

Roche Diagnostics GmbH


Signature

Dr. Manfred Weber

Print Name

Senior Director

Position or Title